Counsel to LAVA Therapeutics in Multimillion-Dollar Global License Agreement
Served as IP counsel to client LAVA Therapeutics, a clinical-stage immuno-oncology company, in a multimillion-dollar global license agreement with Seagen, Inc., a world leader and pioneer in antibody-drug conjugate (ADC) therapies. The exclusive license agreement will enable Seagen to develop, manufacture and commercialize LAVA-1223, an advanced preclinical asset that utilizes LAVA’s proprietary Gammabody™ technology to target epidermal growth factor receptor (EGFR)-expressing solid tumors, most commonly associated with colorectal, lung, head and neck cancer.
Patent Portfolio Strategy for University Covering Pharmaceuticals, Life Sciences and Medical Fields
Developed and executed patent filing strategy and managed diverse patent portfolio for a large university client. Technologies span various subject areas including pharmaceuticals, life sciences and medical fields.
Advised on Paragraph (iv) Certification Strategy Related to Development of Generic Pharmaceuticals
Advised in-house counsel on paragraph (iv) certification strategy and provided related opinion work, including noninfringement and invalidity analyses of competitor patents in support of Hatch-Waxman litigation. Further advised on design-around and re-formulation strategies.